Most Awaited Q3 Sale is back. Upto 30% discount on every report.

T-cell-lymphoma Market Size, Share, Industry, Forecast and outlook (2023-2030)

Published: 2023 June 07
SKU : PH1486
195 pages
Report Summary
Table of Contents
List of Tables & Figures

Global T-cell-lymphoma Market is segmented By Type (Peripheral T-cell Lymphoma, Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Others), By Treatment (Radiotherapy, Chemotherapy, Targeted Therapy, Surgery, and Stem Cell Transplantation, Others), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2023-2030


T-cell-lymphoma Market Overview

The T-Cell Lymphoma Market reached USD 1,485.2 million in 2022 and is projected to witness lucrative growth by reaching up to USD 2,787.8 million by 2030. The T-cell lymphoma market is expected to exhibit a CAGR of 8.4% during the forecast period (2023-2030). The increased prevalence of cancer and autoimmune illnesses, the growing older population, and the increase in lymphoma cancer incidence due to radiation together contribute to the expansion of the T-cell lymphoma market.

Rising healthcare expenditure and increasing R&D activities to develop effective T-cell lymphoma-specific therapies are also expected to drive market growth.

The growth of the T-cell lymphoma market is also attributed to the rise in lymphoma cancer incidence due to radiation, an increase in the number of T-cell lymphoma-specific therapies, and the risk of lymphoma due to autoimmune disorders.


T-cell-lymphoma Market Scope 





Size Available for Years


Forecast Period


Data Availability

Value (USD ) 

Segments Covered

By Type, By Treatment 

Regions Covered

North America, Europe, Asia-Pacific, South America and Middle East & Africa

Fastest Growing Region


Largest Region

North America

Report Insights Covered

Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter’s Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis and Other key Insights.


To know more Insights  Download Sample


T-cell-lymphoma Market Dynamics

Increase in Prevalence of T-Cell Lymphoma

The T-cell lymphoma market is growing because radiation is causing more lymphoma cancer, in addition, autoimmune diseases increase the risk of lymphoma. The Leukemia and Lymphoma Society states that 186,400 new cases of leukemia and lymphoma will be found in people living in the United States in the year 2021.

In the United States, there were also 825,651 people living with lymphoma, 152,671 of whom had Hodgkin lymphoma and 672,980 of whom had non-Hodgkin lymphoma. T-cell lymphoma is a big reason why non-Hodgkin lymphoma happens, which in turn contributes a lot to the growth of the market as a whole.

High Cost and Long Duration of Treatment

One of the main restraints of the T-cell lymphoma market is high cost and long duration of treatment whereas many poor patients cannot afford the treatment. Also, there is a lack of awareness in rural areas regarding the therapeutic process for cancer disease, which is another restraint in the T-cell lymphoma market. 


T-cell-lymphoma Market Segment Analysis

The Chemotherapy Segment will Dominate the Market in the Forecast Period

The T-Cell lymphoma market is divided into categories based on the type of therapy used: radiotherapy, chemotherapy, immunotherapy, stem cell transplantation, and other types of therapies. Due to the high disease incidence, the chemotherapy sector held the biggest market share at 40.8%.

Chemotherapy is a medication that is frequently employed to treat lymphoma. The development of cancer cells is inhibited and slowed. Chemotherapy has the ability to treat the entire body, in contrast to surgery and radiation therapy. In a specific area of the body, these treatments can eliminate or kill cancer cells.

Source: DataM Intelligence Analysis (2023)


T-cell-lymphoma Market Geographical Penetration

North America Will be the Dominating Region During the Forecast Period.

In terms of revenue and market share, North America controls a large portion of the T-cell lymphoma treatment market, and this dominance is expected to capture a market of around 42.4% during the projection period. This is because this area has a strong healthcare infrastructure and a number of important essential stakeholders.

The quick discovery and introduction of novel medicines by significant market participants to treat cancer as well as the sizable patient pool affected by cancer are the main drivers of the market growth rate in the United States.


Source: DataM Intelligence Analysis (2023)


T-cell-lymphoma Companies

The major global players include Johnson & Johnson, Novartis, Bristol Myers Squibb, Merck, F.Hoffmann La Roche, Acrotech Biopharma, GlaxoSmithKline, and Spectrum Pharmaceuticals.


COVID-19 Impact on T-cell-lymphoma Market 

Due to the COVID-19 epidemic, patients with cutaneous lymphomas were at an increased risk of missing receiving crucial diagnostic tests and treatments, either because hospitals were difficult for them to access or because of a lack of available healthcare resources.

Key Developments

  • In April 2023, Fresenius Kabi launched single-needle option for the amicus extracorporeal photopheresis protocol. Fresenius Kabi is a global health care company that specializes in medicines and technologies for infusion, transfusion and clinical nutrition. Extracorporeal photopheresis or ECP is a leukapheresis-based therapeutic procedure. The technology is currently approved for the treatment of cutaneous T-cell lymphoma (CTCL).
  • In May 2023, Shorla Oncology, a U.S.-Ireland pharmaceutical company, and EVERSANA, a leading provider of commercialization services to the life science industry, announced the commercial launch of the company's oncology drug, Nelarabine Injection, for the treatment of T-cell Acute Lymphoblastic Leukemia (T-ALL) and T-cell Lymphoblastic Lymphoma (T-LBL) in adult and pediatric patients aged one year and older whose disease has not responded to or has relapsed following treatment with at least two chemotherapy regimens. 

Why Purchase the Report?

  • To visualize the T-cell lymphoma market segmentation based on the type, treatment and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development. 
  • Excel data sheet with numerous data points of T-cell lymphoma market level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global T-cell lymphoma market drugs market report would provide approximately 92 tables, 108 figures and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Suggestions for Related Report

For more Biotechnology related reports, Please Click Here

Buy this report
Single User
Multiple User
Enterprise User
Proceed to Buy
Request new version
What is the Projected CAGR value of the T-cell-lymphoma Market ?
T-cell-lymphoma Market is expected to grow at a CAGR of 8.5% during the forecasting period 2023-2030.
Who are the key players of T-cell-lymphoma Market ?
The major global players include Johnson & Johnson, Novartis, Bristol Myers Squibb, Merck, F.Hoffmann La Roche, Acrotech Biopharma, GlaxoSmithKline, and Spectrum Pharmaceuticals.
Which region controlled the global market during 2023-2030?
North America region Controls the T-cell-lymphoma Market during 2023-2030.
Which is the fastest growing region in the T-cell-lymphoma Market ?
Among all regions, Asia Pacific is the fastest growing market share during the forecast period.